| 证券代码 | KBLMR.O |
| 证券名称 | KBL Merger Corp IV Rt |
| 证券类型 | 美国权利 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2017-06-27 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | - |
| 公司名称 | 180 Life Sciences Corp. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 527 Stanton Christiana Rd., Newark, Delaware, USA |
| 成立日期 | 2016-09-07 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.180lifesciences.com |
| 电话 | +1 (678) 570-6791 |
| 传真 | - |
| 公司简介 | 180 Life Sciences Corp. (formerly:KBL Merger Corp. IV ) is a blank check company organized under the laws of the State of Delaware on September 7, 2016. They were formed for the purpose of effecting a merger, capital stock exchange, stock purchase, asset acquisition or other similar business combination with one or more operating businesses, which they refer throughout this report as their initial business combination. They intend to focus their efforts on acquiring an operating company in the healthcare and related wellness industry although their efforts in identifying a prospective target business will not be limited to a particular industry. |